Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shen Hui Min, Wang Lei, Chen Jia Jun, Zhang Shao Yan, Yang Xu Guang, Zhang Tong, Zheng Pei Yong, Lu Zhen Hui & Huang Xing. (2023) Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy. Expert Opinion on Investigational Drugs 32:8, pages 723-739.
Read now
Read now
Articles from other publishers (5)
Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini & Mehdi Karimi‐Shahri. (2024)
RGD
peptide in cancer targeting: Benefits, challenges, solutions, and possible
integrin–RGD
interactions
. Cancer Medicine 13:2.
Crossref
Crossref
Humayra Afrin, Renu Geetha Bai, Raj Kumar, Sheikh Shafin Ahmad, Sandeep K. Agarwal & Md Nurunnabi. (2023) Oral delivery of RNAi for cancer therapy. Cancer and Metastasis Reviews 42:3, pages 699-724.
Crossref
Crossref
Yajie Liao, Xudong Wu, Mengyu Wu, Yuan Fang, Jie Li & Weiqiang Tang. (2022) Non-coding RNAs in lung cancer: emerging regulators of angiogenesis. Journal of Translational Medicine 20:1.
Crossref
Crossref
Olga A. Sukocheva, Junqi Liu, Margarita E. Neganova, Narasimha M. Beeraka, Yulia R. Aleksandrova, Prasath Manogaran, Ekaterina M. Grigorevskikh, Vladimir N. Chubarev & Ruitai Fan. (2022) Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Seminars in Cancer Biology 86, pages 358-375.
Crossref
Crossref
Hailong Tian, Tingting Zhang, Siyuan Qin, Zhao Huang, Li Zhou, Jiayan Shi, Edouard C. Nice, Na Xie, Canhua Huang & Zhisen Shen. (2022) Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. Journal of Hematology & Oncology 15:1.
Crossref
Crossref